| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Michael Sakalian | |
| David E Martin | |||
| Karl Salzwedel | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus structure | Q55568924 |
| P304 | page(s) | 162-72 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | AIDS Reviews | Q21042370 |
| P1476 | title | Maturation inhibitors: a new therapeutic class targets the virus structure | |
| P478 | volume | 9 |
| Q33560406 | A simple fluorescence based assay for quantification of human immunodeficiency virus particle release |
| Q33819240 | Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets |
| Q36020992 | Antiretroviral drugs: critical issues and recent advances |
| Q42616360 | Combination therapies for traumatic brain injury: prospective considerations |
| Q36950909 | Contributions of Charged Residues in Structurally Dynamic Capsid Surface Loops to Rous Sarcoma Virus Assembly |
| Q28473451 | Drug-class specific impact of antivirals on the reproductive capacity of HIV |
| Q37704408 | Dynamic and geometric analyses of Nudaurelia capensis ω virus maturation reveal the energy landscape of particle transitions |
| Q33653971 | FIV Gag: virus assembly and host-cell interactions |
| Q41822002 | Functional conservation of HIV-1 Gag: implications for rational drug design |
| Q37447762 | HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. |
| Q38539565 | HIV-1 assembly, release and maturation. |
| Q35992805 | Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage. |
| Q35832693 | Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice. |
| Q37192174 | Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457) |
| Q24617174 | Improved Bevirimat resistance prediction by combination of structural and sequence-based classifiers |
| Q35184863 | In vitro analysis of human immunodeficiency virus particle dissociation: gag proteolytic processing influences dissociation kinetics |
| Q35261158 | Last stop before exit - hepatitis C assembly and release as antiviral drug targets |
| Q37592317 | Magic angle spinning NMR reveals sequence-dependent structural plasticity, dynamics, and the spacer peptide 1 conformation in HIV-1 capsid protein assemblies |
| Q28554482 | Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors |
| Q37967727 | Morphogenesis of the Infectious HIV-1 Virion |
| Q37450688 | New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation |
| Q37359650 | No exit: targeting the budding process to inhibit filovirus replication |
| Q33624690 | Novel approaches to inhibiting HIV-1 replication. |
| Q26771739 | Pharmacological intervention of HIV-1 maturation |
| Q33864444 | Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat |
| Q21284351 | Predicting Bevirimat resistance of HIV-1 from genotype |
| Q36967857 | Recent progress in antiretrovirals--lessons from resistance |
| Q90646261 | Resistance to Second-Generation HIV-1 Maturation Inhibitors |
| Q36109547 | SHIVA - a web application for drug resistance and tropism testing in HIV. |
| Q57799419 | Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial |
| Q39017883 | Structural biology of supramolecular assemblies by magic-angle spinning NMR spectroscopy |
| Q35119102 | Structure and stoichiometry of template-directed recombinant HIV-1 Gag particles |
| Q42202820 | Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1 |
| Q33557807 | The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical Isolates |
| Q21245046 | The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles |
| Q24642446 | Virus maturation as a new HIV-1 therapeutic target |
Search more.